[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-346776-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-346776-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","fecal-microbiota-transplantation-combined-with-anti-pd-1-therapy-in-refractory-microsatellite-stable-gastric-cancer-a-phase-i-feasibility-and-safety-study","Fecal Microbiota Transplantation combined with anti-PD-1 therapy in refractory microsatellite-stable gastric cancer - a phase I feasibility and safety study","","This phase I open-label, single-arm, single-center study evaluates fecal microbiota transplantation (FMT) from healthy donors combined with anti-PD-1 therapy in 10 patients with advanced gastrointestinal cancers refractory to anti-PD-(L)1. Participants received initial oral FMT capsules, then maintenance FMT paired with nivolumab across six cycles, with serial fecal and blood biomarker assessments. The combination showed good tolerability without serious adverse events, with objective response 20% and disease control 40%, linked to donor-derived immunogenic colonization and activated immune profiles, including predictive microbial signatures validated independently.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/fecal-microbiota-transplantation-combined-with-anti-pd-1-therapy-in-refractory-microsatellite-stable-gastric-cancer-a-phase-i-feasibility-and-safety-study/346776/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/fecal-microbiota-transplantation-combined-with-anti-pd-1-therapy-in-refractory-microsatellite-stable-gastric-cancer-a-phase-i-feasibility-and-safety-study/346776.png","ImageObject",300,407,{"name":42,"@type":43},"Ivy","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",14,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does this phase I study evaluate?","Question",{"text":63,"@type":64},"It assesses the feasibility and safety of combining fecal microbiota transplantation (FMT) from healthy donors with anti-PD-1 therapy in patients with ICI-refractory microsatellite-stable gastric cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were treatments administered in the study?",{"text":68,"@type":64},"Patients first received oral capsules of FMT, followed by a combination phase where maintenance FMT was paired with nivolumab every two weeks for six cycles.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main safety and efficacy findings?",{"text":72,"@type":64},"The combination was well tolerated with no serious adverse events. Preliminary efficacy included an objective response rate of 20% and a disease control rate of 40%.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},346776,1790436803,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":26,"preview_urls":147},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","Open access Original research  \n Fecal microbiota transplantation  \ncombined with anti-PD-1 therapy in refractory microsatellite-stable gastric cancer: a phase I feasibility and safety study  \nYifan Zhang  ,1 Xiaomin Xu,2 Shulin Wang,2 Xiaochen Yin,2 Bohan Zhang,1 Zhengnong Zhu,2 Rujie Ji,2 Jing Zhu,2 Hermione He,2 Siyuan Cheng,1 Zihan Han,1,3 Tong Xie,1 Xiaotian Zhang,4 Yakun Wang,4 Si Shen,2 Yan Kou,2 Siyu Bao,2 Yingyu Liu,2 Baoran Cao,2 Christophe Bonny,2 Xiaohuan Guo,5 Eran Segal,6 Yan Tan,2 Lin Shen  ,7 Zhi Peng4  \nTo cite: Zhang Y, Xu X,  \nWang S, et al. Fecal microbiota transplantation combined with anti-PD-1 therapy in refractory microsatellite-stable gastric cancer: a phase I feasibility and safety study. Journal for ImmunoTherapy of Cancer 2026;14:e013823 . doi:10 . 1136/ jitc-2025-013823  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2025-013823](jitc-2025-013823)) .  \nYZ, XX, SW, XY and BZ contributed equally. Accepted 21 February 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nProfessor Zhi Peng; [zhipeng@bjmu.edu.cn](zhipeng@bjmu.edu.cn)  \nProfessor Lin Shen; [shenlin@bjmu.edu.cn](shenlin@bjmu.edu.cn)  \nDr Yan Tan; [yant@xbiome.com](yant@xbiome.com)  \nProfessor Eran Segal;  \n[eran.segal@weizmann.ac.il](eran.segal@weizmann.ac.il)  \nABSTRACT  \nBackground The discovery and therapeutic application of immune checkpoint inhibitors (ICIs) have significantly improved clinical outcomes in cancer treatment.  \nHowever, the response rate is still low in gastrointestinal (GI) cancers. The gut microbiome’s impact on immune modulation is a promising area for overcoming resistance to immunotherapy.  \nMethods This study (NCT04130763) is an open-label, single-arm, single-center, phase I study assessing the safety and efficacy of fecal microbiota transplantation (FMT) from healthy donors in 10 patients with advanced GI cancer resistant to anti-programmed death-ligand 1 (PD-(L)1) treatment. 10 patients with histologically confirmed, unresectable, or metastatic GI cancers (8 gastric, 2 colorectal) who were refractory to anti-PD-(L)1 treatment were enrolled. Patients received initial FMT treatment via oral capsules (60 capsules), followed by a combination therapy phase, where maintenance FMT (10 capsules per treatment) was paired with nivolumab at 3 mg/kg every 2 weeks for six cycles. Serial biomarker assessments were conducted through both fecal and blood sampling.  \nResults The combination of FMT and anti-PD-1 treatment was well tolerated with no serious adverse events. The objective response rate was 20% and the disease control rate was 40% . Clinical benefits were associated with colonization of donor-derived immunogenic microbes, and an activated immune status reflected by peripheral immune cell populations. Moreover, microbial signatures were identified for anti-programmed cell death protein-1 (PD-1) responsiveness and validated in an independent cohort.  \nConclusions This phase I study demonstrates the feasibility and safety of combining FMT with anti-PD-1 therapy in patients with ICI-refractory gastric cancer. The observed preliminary efficacy signals and identified microbial signatures generate hypotheses for future trials to investigate microbiome-based approaches to enhance immunotherapy efficacy.  \nTrial registration number NCT04130763.  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n⇒ Immune checkpoint inhibitors (ICIs) have limited efficacy in gastrointestinal (GI) cancers, with low response rates and a high prevalence of acquired resistance. The gut microbiome is a known regulator of ICI response, a concept demonstrated in melanoma where fecal microbiota transplantation (FMT) from responders can overcome resista","cbCaidr5l6uUBCE7","https://ap.wps.com/l/cbCaidr5l6uUBCE7","pdf",5191855,15,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# What Is Already Known on This Topic\n# Introduction\n# What This Study Adds\n# How This Study Might Affect Research, Practice or Policy","[{\"question\":\"What does this phase I study evaluate?\",\"answer\":\"It assesses the feasibility and safety of combining fecal microbiota transplantation (FMT) from healthy donors with anti-PD-1 therapy in patients with ICI-refractory microsatellite-stable gastric cancer.\"},{\"question\":\"How were treatments administered in the study?\",\"answer\":\"Patients first received oral capsules of FMT, followed by a combination phase where maintenance FMT was paired with nivolumab every two weeks for six cycles.\"},{\"question\":\"What were the main safety and efficacy findings?\",\"answer\":\"The combination was well tolerated with no serious adverse events. Preliminary efficacy included an objective response rate of 20% and a disease control rate of 40%.\"}]","Fecal Microbiota Transplantation combined with anti-PD-1 therapy in refractory microsatellite-stable gastric cancer - a phase I feasibility and safety study | PDF",1790062706,38,[148,152],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/617f53eb1adfc2ddb83fee14bcd1c09f.webp",983,1310,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/62973b8fe32dbd14f6889317d54f37cf.webp",982,1309]